Alnylam Pharmaceuticals Inc Stock, NASDAQ:ALNY
675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142
Number of Employees: 1453
Alnylam Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.